Strong Strong Buy - AMX Res. - 500 Beiträge pro Seite

[andrecon]

AMX Res. 906545
erst seit einigen Tagen im deutschen Handel
mit enormen Perfomance Aussichten

Nach den neuesten Analyse und den neuesten Meldungen
eine der interessantesten
aber natürlich auch (spekulativen) Aktien.
Allerdings sollte man nicht vergessen daß diese
Aktie ein enormes Potential vor sich hat und
eine zur Zeit gute Absicherung nach unten hat.
No risk - no fun
Aber ich denke trotzdemer nächste Highflyer ??
kurzfristiges Potential nach Research auf 1 Euro.

Wer hält mit ?:

In den nächsten Tagen wißt Ihr warum ....

[Feritrust]

Was machen die den schönes? Und was macht die gerade so interessant.
Schau dir lieber mal an was bei Provalis abläuft.



Beitrag:
lesen und auch mal den 3y-london-chart anschauen...
quelle: http://www.abg59.dial.pipex.com/Provalis.htm




Provalis plc (formerly Cortecs plc). Cortecs was founded in Australia with A$4 million in 1985, it was listed on the Australian stock exchange in 1986, full ADR listing on Nasdaq in 1993 and listed on the London stock exchange in 1994. Provalis is an integrated medical Diagnostics and Healthcare company whose aim is the research, diagnosis and treatment of disease. During Q3 1999 Provalis dramatically revised it`s strategy. As Cortecs the company model was therapeutic development linked to cyclical funding and news flow. Now Provalis the newly restructured company is driven by operational profit from its Diagnostics and Healthcare divisions which then fund the Therapeutic R&D operation which has been remodelled.

Provalis has three businesses: Provalis Diagnostics (a fully integrated international business encompassing R&D, manufacture and distribution through marketing partners). Provalis Healthcare, an ethical pharmaceutical company focused currently on the U.K. market specialising in the sales and marketing of branded prescription products. Provalis Research and Development, a therapeutic R&D company focused on the development of vaccines for infectious diseases and oral anti-hyperglycaemics



21 December 1999 - Provalis General Annual Meeting.
At the AGM held today, Frank Harding, Chairman, made the following statement:
"Since the issue of the Offer document I am pleased to say that we have secured an important deal with SmithKline Beecham on the licence of some of our vaccine technology. We announced this on 3rd November. This was an important event for the Company as it helped to validate the value of our vaccine portfolio and our revised approach to R&D. This outsourced approach to R&D, with strong collaboration with development partners, has got off to a good start under our new R&D Director Dr Les Davies.
Dr Davies is now working with Phil Gould to establish a Scientific Advisory Board from the Company. We now have a number of academic and industry trained scientists that have agreed to join that Board and we expect to make a formal announcement of its composition shortly. This will then ensure that as well as providing valuable input to the Company`s strategy and direction in our R&D programmes, we comply fully with the new BIA code of practice for Companies such as ourselves.
Many of you will be keen to know of the latest news on our development products Macrulintm and Pseudostattm. We have now prepared partner packs on these products and the Executive team is beginning to talk to other Companies who may partner these developments. The Macrulintm project in particular has a demanding and costly development programme and at the present stage of its development, the Company cannot undertake a high risk project such as this without a collaboration from a partner Company. During 2000 we will seek to identify a suitable partners based on our clinical research data. I am pleased to say since the Offer document the Company has augmented its formulation patents on Macrulintm.
With Pseudostattm we still await the outcome of our application to the F&DA on the orphan drug status with the project but have now begun some further contracted pre-clinical work in the USA. These outcomes are important if we are to secure a partner for the project.Part of our strategy was to allow our Operating Divisions; Healthcare and Medical Diagnostics to focus on the generation of sales. We have now focused our Healthcare Division on ethical pharmaceutical sales and I am pleased to report that since the Offer document and Annual Report we have now agreed the disposal of our non-core over the counter pharmaceutical sales businesses, Chancellor Group and Consolidated Chemicals, for £760,000. Regrettably this has lead to a closure of our Wrexham manufacturing business and we intend to close that site by February 2000. This now brings the asset disposal income for calendar 1999 to £4.6million, which will enable us to sustain our R&D programmes whilst using new funds to support the Operating parts of our business.
The Healthcare Division continues to perform strongly with record sales and a movement to net profit. Sales are growing strongly and we have maintained our growing movement in to net profit for that business. The Falk range of gastroenterological products has continued to sell well and we are seeing encouraging growth in the sale of CALCEOS and CLOTAM. In the next year we expect that we will begin to expand the sales force and license new products for sale.
The news on our Medical Diagnostics Division since the Offer document has been more mixed. We launched both Osteosal and Glycosal at Medica - the largest medical diagnostic exhibition in Europe, in late November and got an overwhelmingly positive response to both products. I am pleased to say that we have now launched Osteosal in the UK using a contracted sales force and we expect the first sales by year-end. Distribution contracts are now in place for a number of markets in Europe and we now also have the product launched in South Korea with encouraging repeat orders. We have however run into difficulties on our plans for the launch of the product in Germany with the Distributor IMACO. They were unable to meet certain criteria laid out for the launch plan for the product. We have therefore decided to terminate that distribution contract and we are already in discussion with a new distributor in Germany.
We have been active, post Medica, in beginning to identify distribution partners for Glycosal, which has now completed all its field clinical testing, and independent laboratory assessments. I am pleased to report that the recent independent assessment of Glycosal by the European Centre for glycated haemoglobin testing has given this diagnostic product an `excellent` rating.
The next year 2000 promises to be an exciting year for the newly formed Provalis."
13 December 1999 - Provalis plc-Provalis disposes of its remaining non-core businesses and refocuses its Healthcare Division on sales and marketing of ethical pharmaceuticals
Provalis plc today announces the latest step in its restructuring to an integrated healthcare company focusing on Pharmaceutical sales and marketing, Medical Diagnostics and Therapeutic R&D. The Company has agreed to sell certain assets used by Chancellor Group Limited and Consolidated Chemicals Limited, its non-core pharmaceutical businesses, to Ayrton Saunders Ltd for £760,000. This sale, completion of which will, under the terms of the agreement, take place on 4th January 2000, will allow Provalis` Healthcare Division to focus on its retained ethical pharmaceuticals sales and marketing business, which has been trading profitably since June 1999. These profits result from stronger sales, improved cost management and contributions from product launches. Following this sale, Provalis` manufacturing facilities at Wrexham, North Wales, will be closed, with the retained ethical pharmaceutical sales and marketing business being managed from Provalis` centralised head office at Deeside. Dr Phil Gould, Chief Executive Officer of Provalis, commented: "We announced our intention to dispose of Chancellor and Consolidated at the announcement of our Preliminary results in October, in line with our new strategy for Provalis. We are now ideally positioned to grow our profitable Healthcare Division, to focus on the launch of our core medical diagnostic products and to exploit the value of its therapeutic product portfolio, particularly in vaccines."

19 November 1999 - Provalis plc-Shareholders approve change of name to Provalis plc
On 27 October 1999, Cortecs plc (the "Company") announced the Placing and Open Offer of 36,614,872 new ordinary shares of 1p each ("Offer Shares"), together with a Capital Reorganisation and a change of name to Provalis plc. At an extraordinary general meeting of the Company held earlier today, all the resolutions proposed were approved. It is expected that the new ordinary shares to be issued pursuant to the Capital Reorganisation, together with the Offer Shares, will be admitted to listing on the London Stock Exchange on 22 November 1999. CREST stock accounts are also expected to be credited on that date. Definitive share certificates in respect of the Offer Shares are expected to be posted, where applicable, by 1 December 1999. Dr Phil Gould, Chief Executive of Provalis plc, commented: "We are delighted that our shareholders have approved the various actions which we have proposed and provided the financial backing to take the restructured company forward. We believe that the revised structure, strategy and business model, which are focused on income growth and partnering, are the most appropriate to enable Provalis to bring its key products to market and deliver the benefits of commercialisation to shareholders.
"The money that we have raised from both existing and new shareholders will be used to grow the healthcare business and launch our new diagnostics products. The recently completed agreement with SmithKline Beecham further demonstrates the value which exists in our therapeutics business."
Certain of the foregoing statements, including those relating to expected income growth and the expected benefits of the Company`s new strategy to shareholders, constitute "forward-looking statements" (as defined in the U.S. Private Securities Litigation Reform Act of 1995). By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. There are a number of important factors that could cause our future results and development to differ materially from those expressed in, or implied by, those forward-looking statements, including the approval of our products by relevant regulatory authorities, our ability to identify and enter into agreements with appropriate partners to bring key products to market and our ongoing costs and expenses. We undertake no obligation to update or revise publicly any forward-looking statements.
18 November 1999 - Cortecs plc- Results of Placing and Open Offer

The Open Offer to Qualifying Shareholders of Cortecs plc of 36,614,872 new ordinary shares of 1p each ("Offer Shares") at 15p per share closed at 3.00 p.m. on Wednesday 17 November 1999. Applications were received in respect of 18,955,402 new ordinary shares, representing 51.77% of the Offer Shares. The Placing and Open Offer will raise £5.0 million after expenses.
All the Offer Shares had been placed with institutional and other investors. Following the closing of the Open Offer, 17,659,470 new ordinary shares will be taken up by those institutional and other investors.
The Placing and Open Offer is subject to the approval of shareholders at an Extraordinary General Meeting to be held on Friday, 19th November 1999. Dr Phil Gould, Chief Executive of Cortecs plc, commented: "The results of the fundraising demonstrate the support of both existing and new shareholders for our revised structure and business model. We are proposing to reflect these changes further by renaming the Company as Provalis plc. "The net proceeds of the Placing and Open Offer will be used to implement the Board`s new strategy, which involves greater focus on the healthcare and medical diagnostics businesses, whilst retaining the long term potential of the therapeutic research and development activities."

4th November 1999- Cortecs plc- Signs agreement with SmithKline Beecham

Cortecs plc announced that it has signed a licensing agreement with SmithKline Beecham. The agreement grants SB exclusive rights to use Cortecs` proprietary antigen technology for the development and commercialisation of vaccines to prevent diseases caused by Haemophilis influenza and Moraxella cattarhalis in children. The most common disease caused by these bacterial pathogens is Ottis Media ( inflammation of the middle ear), which in the USA is estimated to affect three out of four children under the age of three and is estimated to cost $3-4 billion per year in treatment. Under the terms of the agreement, SB will make up-front and milestone payments to Cortecs and will pay royalties on world-wide sales of any products brought to market. SB, would under the terms of the agreement, also reimburse Cortecs` financial obligations over the next three years relating to the Australian Grant Agreement, under which Cortecs and the Commonwealth of Australia are jointly funding research into Ottis Media vaccines at the University of Canberra. All financial terms of the agreement are subject to confidentiality and consequently have not been disclosed.

20th September 1999- Cortecs plc- Release of £1.1m from disposal

Cortecs announced today the sale of its 75% holding of OraTol Ltd by way of a share buy-back by OraTol for £1.1 Million in cash, conditional only on OraTol complying with statutory requirements relating to such a transaction. The intellectual property relating to the antigen delivery technology platform, which was licensed to OraTol when the Cortecs was established in May 1998, will be returned to Cortecs. The remaining 25% equity stake in OraTol is held by a number of investment funds. Dr Phil Gould, chief executive officer of Cortecs commented: "The completion of this transaction continues our programme of disposing of non-core assets and brings the inflow of funds in the last quarter to a total of £3,700,00. The balance of these monies has been generated by the sales of our non-core BioKits Food Diagnostics and Laboratory Services businesses for £1 million, plus a milestone payment of £1,600,000 from TOWA, in respect of the Company`s discontinued development of Macritonin"

21st June 1999- Cortecs plc- Cortecs disposes of two non-core businesses

Cortecs plc today announced further steps in its restructuring as a life science company. Cortecs is selling Food Kits (BioKits) and Cortecs Laboratory Services, two of its non core businesses, to Tepnel Life Sciences plc, for £1,000,000 payable in cash. The net assets disposed of were valued at £510,000, excluding the value attributable to goodwill and know-how. As part of the transaction, nineteen staff based at Deeside, Cotecs` headquarters and R&D centre, will now transfer their employment to Tepnel. Audited accounts for year 30th June 1998 showed net profits before tax of £96,920 for the two businesses.

Cortecs FoodKits (BioKits), formerly part of Cortecs Diagnostics, manufactures and markets kits for the testing of food substances and food composition, contaminant and adulterants. The activities of Cortecs Laboratory Services Limited involve the testing of food for microbiological contamination on a laboratory service basis.

28th January 1999- Cortecs plc- Cortecs appoints Chief executive

Cortecs announced today the appointment of Dr Phil Gould as Chief executive. Dr Gould assumed the responsibility of Acting Chief executive and was appointed to the board on 1st December 1998. Dr Gould joined Cortecs as Director of research and development in January 1998 from Glaxo Wellcome where he was Head of New product Introduction and Product Technology.

Commenting on the appointment, Lord Patten, Non-executive chairman of Cortecs said: "Since he became acting Chief executive in December 1998, Dr Gould has vigorously driven the process of re-organisation of the company, including a review of the product portfolio and the centralisation of all corporate activities in the Deeside area. Dr Gould has both the management skills and the industry experience needed to drive forward the commercialisation of Cortecs` lead products, as well as the scientific expertise to develop Cortecs` drug development pipeline and platform technologies".

20th January 1999-Cortecs plc- Agreement with Merck KGaA

Cortecs announced that it has signed a distribution agreement with Merck KGaA for its subsidiary Merck Farma y Quimica SA to be a second potential manufacturer and distributor in Spain of Macritonin, Cortecs` oral calcitonin capsule product. Merck has agreed terms with Cortecs which include the upfront payment of £100,000 to support development together with a payment of £400,000 refundable in certain circumstances. A further £1 million is payable on the grant of marketing authorisation in Spain. Cortecs has submitted a registration application document for Macritonin in Spain in November 1997. Merck will now participate in the registration process, alongside Ferner international S.A, Cortecs` existing distribution partner in Spain.

1st December 1998- Evaluation of all company programmes

Following an internal review of all the Company`s programmes and some recent findings, it has become evident that two of the three programmes are not as advanced as has previously been indicated. In particular a review of the status of Macritonin shows that: Cortecs has ongoing registration application based on a 400iu dose in six European countries. A decision from the regulatory authority in one of these is anticipated by the end of Q1 1999. If such registration is not granted, then reapplication will probably be required under recently adopted European guidelines, which would delay significantly any product registration. New clinical trials would be required to support applications in some countries, including North America. Such osteoporosis trials would require the collection of bone fracture data and the further investigation of higher doses. Submission of New Drug Application in the USA is not expected before 2004. Higher dosage levels coupled with the present cost of raw materials and manufacturing could place the profitability of Macritonin under threat, particularly in the early years.

On Pseudostat, Cortecs had previously presented data and had run phase II trials in Australia. Following a further review of these studies and the change to GMP biomass material, Cortecs has initiated more studies in healthy volunteers to obtain more data on dose definition and dose scheduling and further preclinical studies on cross protection. It expects to re-enter phase II studies in cystic fibrosis in Q3 1999. Consistent with this Cortecs has recently filed for Orphan Drug Designation in the USA. Further trials in chronic bronchitis and bronchiectasis will follow if supported by the current series of trials, when further pre-clinical data on cross-protection has been obtained.

29th October 1998- Cortecs plc-Results from one year bone-mineral density data

Cortecs announced the results of a descriptive analysis (i.e with no statistical testing) of one year bone mineral density (BMD) data from its ongoing multi-centre European phase III Macritonin™ trial. The purpose of the analysis was to assist in the calculation of the number of patients that would be required for the planned US phase III Macritonin™ trial. The analysis also provided encouraging data that indicate that Macritonin™ has at least qualitative action on BMD. Macritonin™ is Cortecs` oral calcitonin capsule product. Calcitonin is indicated for the treatment of post menopausal osteoporosis.

The trial and analysis: The trial involves more than 500 women and the analysis included those patients who had reached the one year time-point when the analysis was conducted. The analysis was carried out by an independent Contract Research Organisation and Cortecs has access to only limited information, continuing to remain blinded to the patient data, in order not to prejudice the future statistical management of the ongoing European trial. The following information arises from the analysis:

There is a dose related treatment trend on BMD resulting in Macritonin™ therapy. The two lower doses, 100iu and 200iu of Macritonin™ show little more effect than that produced by the calcium and vitamin D supplements that all patients received in accordance with normal medical practice. Hence the 100iu and 200iu in Macritonin™ dose groups will be dropped from the European trial, whilst the 400iu and 800iu oral dose groups and the 200iu intranasal positive control and placebo groups will continue until the late end points are reached. The optimal daily dose could be 400iu or 800iu and the number of patients required in the US trial should be in the order of 200 patients per dose arm, with BMD as the primary efficacy measure.

3rd June 1998 Cortecs plc- £20 million OraTol limited launch

Cortecs today announced the launch of OraTol Limited a new and independently funded biopharmaceutical company. OraTol will develop novel products for the prevention and treatment of allergies and autoimmune diseases through the process of "toleration", this is the down regulation of the human immune response to antigen. Three years financing of £4.996 million has been arranged for the new company via a subscription for shares in OraTol in Japan and Europe. The subscription values OraTol at £20 million. OraTol has been granted exclusive, specific, worldwide licences to Cortecs proprietary technologies for oral delivery of antigens to achieve tolerisation in the field of allergic and immune diseases.

The OraTol approach for suppressing the disease process is designed to switch the immune response that usually occurs against an allergen into a down regulating response, that is one that suppresses a specific immune or inflammatory response which is causing diseases by attacking the body`s own tissues. There are injectable products available for allergic diseases but a limited understanding of the immunology associated with tolerance therapy has meant that there has been only limited production of oral tolerance products. OraTol proprietary oral tolerance approach may offer a number of important clinical and commercial advantages: Improved specificity for disease, oral delivery in commercially viable doses, reduced risk of adverse reaction and a broad application in allergic and autoimmune diseases.


May 1998 Cortecs signs Glaxowellcome as Macritonin™ distributor in Greece

Cortecs plc today announced that it has signed a distribution agreement for Greece with GlaxoWellcome AEBE for Cortecs oral calcitonin product Macritonin™ for the treatment of post menopausal osteoporosis. The agreement is made up of milestone payments and sales minima worth US$14 million. Cortecs submitted a registration application document for Macritonin™ in Greece in October 1997. GlaxoWellcome will now participate in the registration process in Greece. Cotecs will manufacture and supply the product to GlaxoWellcome Greece. Under the terms of agreement the returns to Cortecs will be similar to those negotiated with Ferrer International in Spain, Towa Pharmaceutical in Japan and Teva Pharmaceutical in Israel.

Dr Nicholas Manasskasis, managing director of GlaxoWellcome, Greece, estimates that the total osteoporosis market in Greece is in the region of US$30 million a year and believes that an oral therapeutic like Macritonin™ has the potential to expand the osteoporosis treatment market there considerably.

4th February 1998 Cortecs plc - further results from Macritonin TM phase III trial

Cortecs plc today announced further results from the analysis of six month clinical data from ongoing trials at four European sites for Macritonin TM phase III trial. Macritonin is Cortecs oral formulation of salmon calcitonin which is a well tolerated treatment for osteoporosis and is currently given by injection or intranasally. The data confirmed that confirmed that there was continuing reduction of bone resorption markers in the 400in Macritonin TM and positive control 200 iu nasal dosage groups after six months of treatment. As in the 3 month analysis there was no statistically significant difference between the 400 iu Macritonin TM and 200 iu nasal groups at six month. All patients in the trials also received 400iu vitamin D and 500 mg calcium. These results will assist Cortecs with the Phase III clinical trials to be discussed with the FDA this month.

Osteoporosis: 3million people in the UK alone suffer from osteoporosis which is caused when the normal process of bone formation and bone resorption (breakdown) becomes out of synchrony, so that there is an imbalance and hence a net loss of bone. After the age of forty bone loss begins to occur relatively slowly but this is accelerated in women following the menopause.


All news information is sourced from official authorised company sources





Kommentar einfügen Zurück zum Forum



Gesamte Diskussion:

[andrecon]

wer auf meine Rat (siehe oben )gestern eingestiegen ist
der hat heute bereits ca. 20% an dem Wert verdient.
Australien gibt eine super Performance vor
Einsteigen ist noch nicht zu spät - sollte aber schnell erfolgen
aufgrund der Nachfrage.
Ab 0,80 ggf. auf Gewinnmitnahmen warten um dann einzusteigen.

[JacksonFive]

Bin zu 0,66 rein und warte jetzt.
Ich denke, daß war noch ein aktzeptabler Einstand.
Also viel Spaß.

[brockerya]